Terms: = Breast cancer AND IHC4 AND Treatment
26 results:
1. Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
Abubakar M; Guo C; Koka H; Zhu B; Deng J; Hu N; Zhou B; Garcia-Closas M; Lu N; Yang XR
Breast Cancer Res Treat; 2021 Sep; 189(2):483-495. PubMed ID: 34185195
[TBL] [Abstract] [Full Text] [Related]
2. The ihc4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?
Harel N; Cheema S; Williams D; Ireland-Jenkin K; Fancourt T; Dodson A; Yeo B
Asia Pac J Clin Oncol; 2021 Aug; 17(4):368-376. PubMed ID: 33567144
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Value of Modified ihc4 Score in Patients with Estrogen Receptor-Positive Metastatic breast cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract] [Full Text] [Related]
4. Gene Expression Assay in the Management of Early breast cancer.
Caputo R; Cianniello D; Giordano A; Piezzo M; Riemma M; Trovò M; Berretta M; De Laurentiis M
Curr Med Chem; 2020; 27(17):2826-2839. PubMed ID: 31804159
[TBL] [Abstract] [Full Text] [Related]
5. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of applying ihc4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Cheang MCU; Bliss JM; Viale G; Speirs V; Palmieri C; Shaaban A; Lønning PE; Morden J; Porta N; Jassem J; van De Velde CJ; Rasmussen BB; Verhoeven D; Bartlett JMS; Coombes RC;
Breast Cancer Res Treat; 2018 Feb; 168(1):169-178. PubMed ID: 29177605
[TBL] [Abstract] [Full Text] [Related]
7. Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ breast cancer.
Heindl A; Sestak I; Naidoo K; Cuzick J; Dowsett M; Yuan Y
J Natl Cancer Inst; 2018 Feb; 110(2):. PubMed ID: 28859291
[TBL] [Abstract] [Full Text] [Related]
8. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
[TBL] [Abstract] [Full Text] [Related]
9. Relationship between ihc4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M
Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240
[TBL] [Abstract] [Full Text] [Related]
10. ihc4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.
Lakhanpal R; Sestak I; Shadbolt B; Bennett GM; Brown M; Phillips T; Zhang Y; Bullman A; Rezo A
Breast; 2016 Oct; 29():147-52. PubMed ID: 27498128
[TBL] [Abstract] [Full Text] [Related]
11. Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.
Sestak I; Dowsett M; Ferree S; Baehner FL; Cuzick J
Breast Cancer Res Treat; 2016 Aug; 159(1):71-8. PubMed ID: 27447876
[TBL] [Abstract] [Full Text] [Related]
12. Comparing breast cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
Bartlett JM; Bayani J; Marshall A; Dunn JA; Campbell A; Cunningham C; Sobol MS; Hall PS; Poole CJ; Cameron DA; Earl HM; Rea DW; Macpherson IR; Canney P; Francis A; McCabe C; Pinder SE; Hughes-Davies L; Makris A; Stein RC;
J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27130929
[TBL] [Abstract] [Full Text] [Related]
13. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A;
Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046
[TBL] [Abstract] [Full Text] [Related]
14. Risk of recurrence estimates with ihc4+C are tolerant of variations in staining and scoring: an analytical validity study.
Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
[TBL] [Abstract] [Full Text] [Related]
15. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF
Breast; 2015 Nov; 24 Suppl 2():S6-S10. PubMed ID: 26238437
[TBL] [Abstract] [Full Text] [Related]
16. Clinical utility of the ihc4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.
Yeo B; Zabaglo L; Hills M; Dodson A; Smith I; Dowsett M
Br J Cancer; 2015 Jul; 113(3):390-5. PubMed ID: 26180920
[TBL] [Abstract] [Full Text] [Related]
17. Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.
Vincent-Salomon A; Benhamo V; Gravier E; Rigaill G; Gruel N; Robin S; de Rycke Y; Mariani O; Pierron G; Gentien D; Reyal F; Cottu P; Fourquet A; Rouzier R; Sastre-Garau X; Delattre O
PLoS One; 2013; 8(10):e76496. PubMed ID: 24143191
[TBL] [Abstract] [Full Text] [Related]
18. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract] [Full Text] [Related]
19. Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Sestak I; Dowsett M; Zabaglo L; Lopez-Knowles E; Ferree S; Cowens JW; Cuzick J
J Natl Cancer Inst; 2013 Oct; 105(19):1504-11. PubMed ID: 24029245
[TBL] [Abstract] [Full Text] [Related]
20. Comparison of PAM50 risk of recurrence score with oncotype DX and ihc4 for predicting risk of distant recurrence after endocrine therapy.
Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
[TBL] [Abstract] [Full Text] [Related]
[Next]
